Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 19/20 | 0.40 |
| ▸ | CTSS | P25774 | 19/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23126956 | 0.85 | CTSL (0.40) | CTSLCTSSCTSK | |
| SCHEMBL30311200 | 0.85 | CTSL (0.40) | CTSLCTSSCTSK | |
| SCHEMBL25760749 | 0.81 | CTSL (0.33) | CTSLCTSSCTSKCTSDBACE1 | |
| SCHEMBL24047010 | 0.81 | CTSL (0.33) | CTSLCTSSCTSKCTSDBACE1 | |
| SCHEMBL23100453 | 0.79 | KEAP1 (0.33) | CTSLCTSSCTSDBACE1 | |
| SCHEMBL23127018 | 0.79 | KEAP1 (0.33) | CTSLCTSSCTSDBACE1 | |
| SCHEMBL14974682 | 0.75 | CTSL (0.34) | CTSLCTSSCTSKCTSDBACE1 | |
| SCHEMBL24047212 | 0.75 | CTSL (0.30) | CTSLCTSS | |
| SCHEMBL23126982 | 0.72 | CTSL (0.36) | CTSLCTSSCTSKBACE1 | |
| SCHEMBL23100449 | 0.72 | CTSL (0.36) | CTSLCTSSCTSKBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596078-B1 | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2023-04-12 | — | — | EP | disclosed |
| US-10953019-B2 | Fused pentacyclic imidazole derivatives as modulators of TNF activity | UCB Biopharma SRL (BE) | 2021-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953019-B2 | Fused pentacyclic imidazole derivatives as modulators of TNF activity | TNF, TNFRSF1A, NFKBIA | CTSL 4215/4885CTSS 3889/4885CTSK 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.